Denali Capital Acquisition Corp. And Longevity Biomedical, Inc. Mutually Agreed To Terminate Business Combination

6/27/24 12:41:36 PM ET

Blank Checks

Finance

Get the next $DECA alert in real time by email

Denali Capital Acquisition Corp. (NASDAQ:DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the "Business Combination Agreement"). The Company and its sponsor intend to seek alternative ways to consummate an initial business combination.

Get the next $DECA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DECA

Date	Price Target	Rating	Analyst

More analyst ratings

$DECA
Press Releases

Fastest customizable press release news feed in the world

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from November 11, 2024, to December 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing o
11/11/24 5:01:32 PM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali
As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator
11/6/24 12:24:36 PM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with
10/28/24 6:00:00 AM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Denali Capital Acquisition Corp. And Longevity Biomedical, Inc. Mutually Agreed To Terminate Business Combination

Chat with this insight

Recent Analyst Ratings for
$DECA

$DECA
SEC Filings

SEC Form 10-Q filed by Denali Capital Acquisition Corp.

SEC Form NT 10-Q filed by Denali Capital Acquisition Corp.

SEC Form 425 filed by Denali Capital Acquisition Corp.

$DECA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Large owner Denali Capital Global Investments Llc

SEC Form 4 filed by Large owner Xu Jiandong

$DECA
Press Releases

Fastest customizable press release news feed in the world

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

$DECA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

$DECA
Market Insights

Live Market Insights

$DECA
Financials

Live finance-specific insights

Denali Capital Acquisition Corp. Extends Deadline To Complete Combination From July 11, 2024 To April 11, 2025

Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut

Trading Halt: Halt status updated at 5:40:00 PM ET: Quotation Resumption: News and Resumption Times

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Denali Capital Acquisition Corp. And Longevity Biomedical, Inc. Mutually Agreed To Terminate Business Combination

Chat with this insight

Recent Analyst Ratings for $DECA

$DECA SEC Filings

SEC Form 10-Q filed by Denali Capital Acquisition Corp.

SEC Form NT 10-Q filed by Denali Capital Acquisition Corp.

SEC Form 425 filed by Denali Capital Acquisition Corp.

$DECA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Large owner Denali Capital Global Investments Llc

SEC Form 4 filed by Large owner Xu Jiandong

$DECA Press Releases

Fastest customizable press release news feed in the world

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

$DECA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

$DECA Market Insights

Live Market Insights

$DECA Financials

Live finance-specific insights

Denali Capital Acquisition Corp. Extends Deadline To Complete Combination From July 11, 2024 To April 11, 2025

Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut

Trading Halt: Halt status updated at 5:40:00 PM ET: Quotation Resumption: News and Resumption Times

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Recent Analyst Ratings for
$DECA

$DECA
SEC Filings

$DECA
Insider Trading

$DECA
Press Releases

$DECA
Large Ownership Changes

$DECA
Market Insights

$DECA
Financials